A mass balance study of [14C]SHR6390 (dalpiciclib), a selective and potent CDK4/6 inhibitor in humans

A mass balance study of [14C]SHR6390 (dalpiciclib), a selective and potent CDK4/6 inhibitor in humans

SHR6390 (dalpiciclib) is a selective and effective cyclin-dependent kinase (CDK) 4/6 inhibitor and an effective cancer therapeutic agent. On 31 December 2021, the new drug application was approved by National Medical Product Administration (NMPA). The metabolism, mass balance, and pharmacokinetics o...

Full description

Bibliographic Details
Main Authors: Hua Zhang, Shu Yan, Yan Zhan, Sheng Ma, Yicong Bian, Shaorong Li, Junjun Tian, Guangze Li, Dafang Zhong, Xingxing Diao, Liyan Miao
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-03-01
Series:Frontiers in Pharmacology
Subjects:
SHR6390
[14C]SHR6390
radioactivity
drug metabolism
CDK
pharmacokinetics
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1116073/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1116073/full

Similar Items